News

search close

Relmada Therapeutics Strengthens Financial Operations with Addition of Maged Shenouda as Chief Financial Officer

Read more

Relmada Therapeutics Strengthens Board of Directors with Appointments of Life Sciences Industry Veterans, Eric Schmidt, Ph.D., and John Glasspool

Read more

Relmada Therapeutics Announces Closing of $115 Million Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Read more

Relmada Therapeutics Announces Pricing of Public Offering of Common Stock

Read more

Relmada Therapeutics Announces Proposed Public Offering of Common Stock

Read more

Relmada to Ring NASDAQ Stock Market Opening Bell on Friday, October 18

Read more

Relmada Therapeutics Announces Top-Line Results from REL-1017 Phase 2 Study in Individuals with Treatment Resistant Depression

Read more

Relmada Therapeutics to Announce Results of Phase 2 Study of REL-1017 for Treatment Resistant Depression and Conduct Conference Call on Tuesday, October 15

Read more

Relmada Therapeutics Announces Commencement of Trading on The NASDAQ Capital Market

Read more

Relmada Therapeutics Announces Uplisting to The NASDAQ Capital Market

Read more
rss_feed News RSS